Viability of carriers of chromosomal abnormalities depends on genomic dosage of active ribosomal genes (rRNA genes)

Viability of carriers of chromosomal abnormalities depends on genomic dosage of active ribosomal... The genomic dosage of active (transcription-capable) ribosomal genes (AcRG) was determined in the genomes of 172 individuals, carriers of various chromosomal abnormalities: 116 individuals with numerical autosomal abnormalities (Down syndrome and Robertson translocations), 36 individuals with numerical abnormalities of gonosomes (Klinefelter, Turner, trisomy X, and disomy Y syndromes), and 20 carriers of various structural abnormalities of chromosomes. In the control sample of healthy individuals with a normal karyotype (N = 318), the AcRG number varied from 120 to 190 copies with mean of 150 ± 1 copies per diploid genome. In all the studied samples of carriers of chromosomal abnormalities, the genomic dosage (GD) of AcRG does not exceed the limits of variation of this feature in the control sample. However, in all the samples, the characteristic differences in the GD of AcRG were revealed. In accordance with the expectation, in patients with Down syndrome, the mean GD of AcRG was 10% higher, and in carriers of Robertson translocations, the maximum AcRG dose was 20% less than in the control. It can be concluded that about 10% of patients with Down syndrome and up to 50% of carriers of Robertsonian translocations die in the prenatal or early postnatal period because of excess or deficiency of AcRG in their genomes. A significant narrowing of the limits of the variation of the GD of AcRG in a sample of age-specific (over 10 years) patients with Down syndrome in comparison with the newborns was revealed. Obviously, Down syndrome carriers with low and high doses of AcRG predominantly die during the first years of life. The GD of AcRG of carriers of numerical anomalies of gonosomes predominantly fall into the region of medium, adaptive doses, and the carriers of structural chromosomal abnormalities predominantly survive when the dose of AcRG in the genome is greater than the mean in the control sample. For the first time, data on the association of the viability of carriers of different variants of chromosomal abnormalities with the number of active copies of rRNA genes in their genomes are presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Russian Journal of Genetics Springer Journals

Viability of carriers of chromosomal abnormalities depends on genomic dosage of active ribosomal genes (rRNA genes)

Loading next page...
 
/lp/springer_journal/viability-of-carriers-of-chromosomal-abnormalities-depends-on-genomic-Pjf1u2dosk
Publisher
Pleiades Publishing
Copyright
Copyright © 2017 by Pleiades Publishing, Inc.
Subject
Biomedicine; Human Genetics; Animal Genetics and Genomics; Microbial Genetics and Genomics
ISSN
1022-7954
eISSN
1608-3369
D.O.I.
10.1134/S1022795417060096
Publisher site
See Article on Publisher Site

Abstract

The genomic dosage of active (transcription-capable) ribosomal genes (AcRG) was determined in the genomes of 172 individuals, carriers of various chromosomal abnormalities: 116 individuals with numerical autosomal abnormalities (Down syndrome and Robertson translocations), 36 individuals with numerical abnormalities of gonosomes (Klinefelter, Turner, trisomy X, and disomy Y syndromes), and 20 carriers of various structural abnormalities of chromosomes. In the control sample of healthy individuals with a normal karyotype (N = 318), the AcRG number varied from 120 to 190 copies with mean of 150 ± 1 copies per diploid genome. In all the studied samples of carriers of chromosomal abnormalities, the genomic dosage (GD) of AcRG does not exceed the limits of variation of this feature in the control sample. However, in all the samples, the characteristic differences in the GD of AcRG were revealed. In accordance with the expectation, in patients with Down syndrome, the mean GD of AcRG was 10% higher, and in carriers of Robertson translocations, the maximum AcRG dose was 20% less than in the control. It can be concluded that about 10% of patients with Down syndrome and up to 50% of carriers of Robertsonian translocations die in the prenatal or early postnatal period because of excess or deficiency of AcRG in their genomes. A significant narrowing of the limits of the variation of the GD of AcRG in a sample of age-specific (over 10 years) patients with Down syndrome in comparison with the newborns was revealed. Obviously, Down syndrome carriers with low and high doses of AcRG predominantly die during the first years of life. The GD of AcRG of carriers of numerical anomalies of gonosomes predominantly fall into the region of medium, adaptive doses, and the carriers of structural chromosomal abnormalities predominantly survive when the dose of AcRG in the genome is greater than the mean in the control sample. For the first time, data on the association of the viability of carriers of different variants of chromosomal abnormalities with the number of active copies of rRNA genes in their genomes are presented.

Journal

Russian Journal of GeneticsSpringer Journals

Published: Jul 12, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off